Abstract
Background
Whole autologous colon cancer vaccines in combination with various adjuvants have been used in both animals and humans. At this writing, vaccine regimens have been initiated in humans 3 to 6 weeks postoperatively. This delay between tumor resection and vaccination gives surviving tumor cells an opportunity to establish themselves. Vaccine administered either preoperatively or immediately after surgery, in theory, should be more effective. However, surgery-related immunosuppression may diminish the effectiveness of preoperative or early postoperative vaccines. This problem may be overcome by limiting postoperative immunosuppression via the use of minimally invasive methods. Alternatively, the impact of the vaccine may be improved by encapsulating the vaccine, plus adjuvant, which in theory, should extend exposure time. Encapsulation of cancer vaccines in polysaccharide particles has not yet been studied. The goal of this study was to determine whether vaccine encapsulation, preoperative vaccination, and early postoperative vaccination affected the tumor burden. In addition, laparotomy and carbon dioxide insufflation were compared.
Methods
Vaccine was prepared from ultraviolet-irradiated C26 colon cancer cells in combination with monophosphoryl lipid A, either in suspension or entrapped in alginate beads. The C26 cell line and syngeneic BALB/c mice were used for all the studies. Tumor volumes were determined after excision of the tumors 2 weeks after inoculation in these studies.
Results
Encapsulated vaccine was more effective than the standard liquid vaccine. Significantly smaller tumors were noted in mice receiving encapsulated vaccine than in either the control group (p<0.01) or the liquid vaccine group (p<0.05). The use of a preoperative encapsulated vaccine was associated with significantly smaller tumors after laparotomy, pneumoperitoneum, or anesthesia alone when the tumors were established immediately after surgery. With an already established tumor, encapsulated vaccine, when given in the early postoperative period to mice that had undergone laparotomy or anesthesia alone was associated with significantly smaller tumors that those found in control animals.
Conclusions
The incorporation of a whole-cell vaccine and monophosphoryl lipid A into alginate beads increases the efficacy of pre-operative and early postoperative tumor vaccines in the setting of both laparotomy and Carbon dioxide pneumoperitoneum. The use of perioperative vaccines may prove to be an effective way to immunize patients with cancer undergoing surgery.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Allendorf JD, Bessler M, Kayton M, Whelan RL, Treat MR (1995) Tumor growth after laparoscopy and laparotomy in a murine model. Arch Surg 130: 649–653
Brown KA, Moser CA, Speaker TJ, Khoury CA, Kirn JE, Offit PA (1995) Enhancement by microencapsulation of rotavirus-specific intestinal immune responses in mice assessed by enzymelinked immunospot assay and intestinal fragment culture. J Infect Dis 171: 1334–1338
Christou NV, Superina R, Broadhead M, Meakins JL (1982) Postoperative depression of host resistance: determinants and effect of peripheral protein-sparing therapy. Surgery 92: 786–792
Gray BN, Walker C, Andrewartha L, Freeman S, Bennett RC (1988) Melbourne trial of adjuvant immunotherapy in operable large bowel cancer. Aust N Z J Surg 58: 43–46
Harris JE, Ryan L, Hoover HC, Stuart RK, Oken MM, Benson AB, Mansour E, Haller DG, Manola J, Hanna MG (2000) Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine. Eastern Cooperative Oncology Group Study E5283. J Clin Oncol 18: 148–157
Haspel MV, McCabe RP, Pomato N, Janesch NJ, Knowlton JV, Peters LC, Hoover HC Jr, Hanna MG Jr (1985) Generation of tumor cell-reactive human monoclonal antibodies using peripheral blood lymphocytes from actively immunized colorectal carcinoma patients. Cancer Res 45: 3951–3961
Hirasawa Y, Kohno N, Yokoyama A, Kondo K, Hiwada K, Miyake M (2000) Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med 161: 589–594
Hoover Hc Jr, Brandhorst JS, Peters LC, Surdyke MG, Takeshita Y, Madariaga J, Muenz LR, Hanna MG Jr (1993) Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 11: 390–399
Hoover HC Jr, Surdyke M, Dangel RB, Peters LC, Hanna MG Jr (1984) Delayed cutaneous hypersensitivity to autologous tumor cells in colorectal cancer patients immunized with an autologous tumor cell: bacillus Calmette-Guerin vaccine. Cancer Res 44: 1671–1676
Khoury CA, Moser CA, Speaker TJ, Offit PA (1995) Oral inoculation of mice with low doses of microencapsulated, noninfectious rotavirus induces virus-specific antibodies in gut-associated lymphoid tissue. J Infect Dis 172: 870–874
Lennard TW, Shenton BK, Borzotta A, Donnelly PK, White M, Gerrie LM, Proud G, Taylor RM (1985) The influence of surgical operations on components of the human immune system. Br J Surg 72: 771–776
Moser CA, Speaker TJ, Berlin JA, Offit PA (1996) Aqueous-based microencapsulation enhances virus-specific humoral immune responses in mice after parenteral inoculation. Vaccine 14: 1235–1238
National Cancer Data Base. American Joint Committee on Cancer manual for staging of cancer. 4th ed. JB Lippincott, Philadelphia, 1992
Ravindranath MH, Bauer PM, Amiri AA, Miri SM, Kelley MC, Jones RC, Morton DL (1997) Cellular cancer vaccine induces delayed-type hypersensitivity reaction and augments antibody response to tumor-associated carbohydrate antigens (sialyl Le [a], sialyl Le [x], GD3 and GM2) better than soluble lysate cancer vaccine. Anticancer Drugs 8: 217–224
Southall JC, Lee SW, Allendorf JD, Bessler M, Whelan RL (1998) Colon adenocarcinoma and B-16 melanoma grow larger following laparotomy vs pneumoperitoneum in a murine model. Dis Colon & Rectum 41: 564–569
Syrigos KN, Charalampopoulos A, Pliarchopoulou K, Syrigou EI, Avuzuklidou M, Manouras A, Leandros M (1999) Prognostic significance of autoantibodies against tropomyosin in patients with colorectal adenocarcinoma. Hybridoma 18: 543–546
Vermorken JB, Claessen AM, van Tinteren H, Gall HE, Ezinga R, Meijer S, Scheper RJ, Meijer CJ, Bloemena E, Ransom JH, Hanna MG, Pinedo HM (1999) Active specific immunotherapy for stage II and stage III human colon cancer: a randomized trial. Lancet 353: 345–345
Whelan RL, Franklin M, Donahue J (1998) Postoperative cell mediated immune response is better preserved after laparoscopic versus open colectomy in human: preliminary study. Surg Endosc 12: 586 [abstract]
Wildbrett P, Oh A, Bessler M, Whelan RL (2000) Increased rates of pulmonary metastases following sham laparotomy compared to CO2 pneumoperitoneum and the inhibition of this effect with perioperative immunomodulation. EAES Meeting, Nice, France
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kirman, I., Asi, Z., Carter, J. et al. Combined whole tumor cell and monophosphoryl lipid A vaccine improved by encapsulation in murine colorectal cancer. Surg Endosc 16, 654–658 (2002). https://doi.org/10.1007/s00464-001-8187-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00464-001-8187-6